Brief: Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon

27/02/2024 13:34

Feb 27 (Reuters) - Imunon Inc  IMNN.O :
    * MEMORIAL SLOAN KETTERING CANCER CENTER NOW ENROLLING
PATIENTS IN
PHASE 1/2 CLINICAL TRIAL OF IMUNON’S IMNN-001 IN COMBINATION
WITH BEVACIZUMAB IN ADVANCED OVARIAN CANCER

Source text for Eikon:  ID:nGNX4qSz5d 
Further company coverage:  IMNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))